

DR MARK PATRICK JOHN VANDERPUMP

Date of birth 30th December 1963

CURRICULUM VITAE

JANUARY 2025

QUALIFICATIONS

1975-1982	Latymer Upper School, Hammersmith, London
1982-1987	University of Birmingham Medical School
1987	MB ChB (Birmingham)
February 1990	MRCP (UK)
December 1995	MD (Birmingham)
October 1996	CCST in General Medicine, Endocrinology and Diabetes
May 2001	FRCP (London)
GMC Registration number:	3181931
Appraisal completed:	19 th January 2025
GMC Registration No: 3181931.	Revalidation date: August 2026
MPS Membership No: 1512647.	Period 1st April 2024 to 31st March 2025
ICO Certificate No: ZA759249	End date 30th March 2025
DBS Certificate No: 001435223241	Expiry date 15th February 2025

PROFESSIONAL APPOINTMENTS

April 2016 to date	Consultant Physician and Endocrinologist in full-time private practice, London. Clinics at OneWelbeck Endocrinology, Wellington Diagnostics Out-Patients Centre, and The Physicians' Clinic.
March 1999 to March 2016	Consultant Physician and Honorary Senior Lecturer in Endocrinology and Diabetes, Royal Free London NHS Foundation Trust
December 1996-March 1999	Consultant Physician with interest in Endocrinology and Diabetes, North Middlesex Hospital NHS Trust
February 1995-December 1996	Senior Registrar in Endocrinology, Diabetes and General Internal Medicine, Stoke-on-Trent (Dr L Alexander, Prof

August 1994-February 1995	RN Clayton & Dr J Scarpello) Registrar in General Internal Medicine, Diabetes and Endocrinology, Northumberland (Dr ET Young)
November 1993-July 1994	Registrar in General Internal Medicine, Diabetes and Endocrinology, Bishop Auckland General Hospital, County Durham (Dr AJ McCulloch & Dr MC Bateson)
November 1991-October 1993	Regional Research Fellow at Newcastle General Hospital and Honorary Research Associate, University of Newcastle (Dr WMG Tunbridge (Supervisor))
August 1990-October 1991	Registrar in General Internal Medicine, Diabetes and Endocrinology, Newcastle General Hospital, (Dr WMG Tunbridge & Dr RM Francis)
August 1998-July 1990	Medical SHO Rotation, Wolverhampton Hospitals, (Dr EM Tilsen (Geriatrics), Dr S Walford (Diabetes and Endocrinology), Dr SJ Connellan & Dr JS Mann (Respiratory), Dr JW Pidgeon (Cardiology)
February 1998-July 1998	Medical Pre-Registration House Officer, Queen Elizabeth Hospital, Birmingham (Dr MA Waite & Prof DR London)
August 1997-January 1998	Surgical Pre-Registration House Officer, Dudley Road Hospital, Birmingham (Mr AO Wilson)

CLINICAL PRACTICE

I resigned from my NHS practice at the Royal Free Hospital in April 2016 after 30 years of service within the NHS. I now work in full-time private practice specialising in out-patient diabetes and endocrinology within Central London at The Physicians' Clinic, OneWelbeck Endocrinology and Wellington Diagnostics Out-Patient Centre.

Medicolegal practice writing 50 expert reports per year (Approximately 1/2 Claimant). Awarded Cardiff University Law School Bond Solon Expert Witness Certificate in October 2020.

President of the British Thyroid Association 2014-17.

Chair of London Consultants' Association Chair 2019-22. Vice Chair 2022 to date.

In my 20-year career as an NHS consultant I had the following commitments:

General endocrine clinic including responsibility for thyroid service, pituitary disorders and reproductive endocrinology.

General diabetes clinic including people with type 1 and complex type 2 diabetes.

Consultant-led clinic in the community in conjunction with a community multidisciplinary diabetes team in Camden. Between 2001-12 I had responsibility for primary care liaison in diabetes in Camden and GP/Practice Nurse teaching programme now exists with guidelines for the management of diabetes and an email support system.

Adolescent Thyroid Clinic at UCL from 2001-2020.

Combined Pituitary Clinic at National Hospital, Queen Square from 1997-2007.

Clinical Director for Medical Specialties including Out-Patient Services 2005-06.

Chair of the Trust European Working Time Directive Service, Training and Care Committee from 2004-07 which implemented the development of a generic night-team within Medicine

and Surgery led by a Nurse Coordinator.

Trust Drugs and Therapeutic Committee 2007-11 and Deputy Chair 2009-11.

Member of Local Awards Committee for Clinical Excellence Awards 2009.

Northwest London representative on the NHS England Commissioning Clinical Reference Group for Specialised Endocrinology 2013-16.

Society for Endocrinology representative on RCP Joint Speciality Committee for Endocrinology and Diabetes Mellitus from 2012-16.

CLINICAL GUIDELINES

1. Vanderpump MPJ, Ahlquist JAO, Franklyn JA & Clayton RN on behalf of a Working Group of the Research Unit of the Royal College of Physicians and the Endocrinology and Diabetes Committee of the College and Society for Endocrinology (1996). Development of consensus for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. *BMJ* 313:539-44.
2. Vanderpump MPJ. Epidemiology of subclinical thyroid disease: Expert advisor for Consensus Development Conference on subclinical thyroid disease, Endocrine Society. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. (2004). *JAMA* 291:228-38.
3. Association of Clinical Biochemistry, British Thyroid Association and British Thyroid Foundation (2006). UK guidelines for the use of thyroid function tests. http://www.british-thyroid-association.org/TFT_guideline_final_version_July_2006.pdf
4. Rajasekaran S, Vanderpump M, Baldeweg S, Drake W, Lanyon M, Markey A, Plant G, Powell M, Sinha S, Wass J. (2011). UK guidelines for the management of pituitary apoplexy. Pituitary Apoplexy Guidelines Development Group. UK guidelines for the management of pituitary apoplexy. *Clin Endocrinol* 74:9-20.
5. Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump M. (2012). The use of L-T4 + L-T3 in the treatment hypothyroidism: Guidelines of the European Thyroid Association. *Eur Thy J* 1:55-71.
6. Okosieme O, Gilbert J, Abraham P, Boelaert K, Dayan C, Gurnell M, Leese G, McCabe C, Perros P, Smith V, Williams G, Vanderpump M. (2016). Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. *Clin Endocrinol* 84:799-808.
7. Baldeweg SE, Vanderpump M, Drake W, Reddy N, Markey A, Plant GT, Powell M, Sinha S, Wass J; Society for Endocrinology Clinical Committee. (2016). Society for Endocrinology Endocrine Emergency Guidance: Emergency management of pituitary apoplexy in adult patients. *Endo Connect* 5:G12-G15.
8. Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Didejczyk A, Links TP, Vanderpump. (2018) European Thyroid Association (ETA) guidelines for the management of amiodarone associated thyroid dysfunction. *Eur Thy J* 7:55-66.

PROFESSIONAL MEMBERSHIP/COMMITTEES

Royal College of Physicians (London).

Diabetes UK.

British Thyroid Association: Assistant Secretary 2001-2002; Secretary 2002-2005; Committee Member 2005-2008; President 2014-2017. Committee Member 2017-2019.

British Thyroid Foundation Trustee 2012-2017.

UK representative of the International Council for the Control of the Iodine Deficiency Disorders and founder member of the UK Iodine Group 2012-20.

UK Iodine Group 2012-2020.

Society for Endocrinology: Member of BES Programme Organising Committee 2003-2005 and BES Liaison Committee Member from 2001-2004. Finance Committee Member 2009-2012.

Association of British Clinical Diabetologists.

London Consultants' Association (Trustee 2014-19; Chair 2019-22; Vice-Chair 2022 onwards).

Independent Doctors Federation.

AUDIT

I have supervised or participated in the following published audits:

1. Audit of strategy of use of TSH alone in thyroid function tests in a DGH laboratory. Vanderpump MPJ, Manning K, Neary RH & Clayton RN (1997).

2. An audit of management of thyroid cancer in a large district general hospital Vanderpump MPJ, Alexander L, Scarpello JH & Clayton RN (1998).

3. Analysis of patient knowledge and effectiveness of insulin stress tests performed in patients with pituitary disease within the Department of Endocrinology of the Royal Free Hospital. Brothwood TA & Vanderpump MP. Safety, accuracy and patients' perspectives of insulin tolerance tests: An audit. Endocrine Society 2001, Endo 2001:P1-627.

4. Single centre audit of surgical outcome in acromegaly. SE Baldeweg, GS Conway, M Powell & M Vanderpump. Endocrine Abstracts (2003) 5:P190.

5. Use of continuous glucose monitoring system in the medical management of insulinomas. Baldeweg SE, Hope S, Tibbals J, Davidson B & Vanderpump M. Endocrine Abstracts (2003) 6:DP23.

6. An audit of hypoglycaemia in insulin treated patients with type 2 diabetes. Hope SJC, Parker C & Vanderpump MPJ. Hypoglycaemia and insulin treated type 2 diabetes - two insulin regimes compared. Diabetes UK 2004, Diabetes Med 21 (Suppl 2):P102.

7. An audit of patients with thyrotoxicosis treated at the Royal Free Hospital has provided data on the relapse rate following treatment with anti-thyroid drugs, radioiodine and surgery as well as providing cost-effectiveness data for the three management approaches. Patel NN, Baker JJ, Abraham P & Vanderpump MPJ. The cost-effectiveness of treatment modalities for thyrotoxicosis - a 2-year follow-up study. ATA 2004, Thyroid: 14:700.

8. Audit and review of the new night-team structure in acute medicine to examine quality of care, training opportunities, leadership and team-building and consultant work-load in conjunction with the Medical Director and Postgraduate Dean.

9. A prospective study using continuous subcutaneous insulin infusion (CSII) for type 1 diabetes at the Royal Free Hospital. Solomon AM, Nethaji C, Holland J, Vanderpump M & Press M. A prospective study using continuous subcutaneous insulin infusion (CSII) for type 1 diabetes in a single centre. *Diabetes UK 2008, Diabetes Med 25, Suppl 1:OC.*
10. Audit of thyroid function testing in a HIV population. Vanderpump MPJ, Kottegoda R, Madge S, Thomas M, Smith C, Lampe F, Harvey R, Johnson M & Youle M. No association between HIV disease and its treatment and thyroid function. *BTA Autumn Meeting 2005 and International Thyroid Congress 2005, Thyroid 15 (Suppl. 1):S79-80, and HIV 2006, HIV Medicine 7 (Suppl.1):P49.*
11. Joint audit with the Department of Clinical Biochemistry to investigate the finding of raised serum FT4 and inappropriately detectable serum TSH. Han TS, Woolman E, Johri N, Thomas M, & Vanderpump MP. Raised serum FT4 and inappropriately detectable serum TSH: Evaluation of recommendations from UK TFT guidelines. *British Endocrine Societies 2008, Endocrine Abstracts 14:P369, and Endo 2008, P1-360.*
12. Joint audit with the Departments of Clinical Biochemistry and Hepatology to determine the incidence of thyroid dysfunction in a Hepatitis C population treated with Interferon and Ribavirin combination therapy. Costelloe S, Wassef N, Morris C, Schulz J, Vaghani T, Thomas M, Jacobs M, Dusheiko G & Vanderpump M. Thyroid dysfunction in a hepatitis C population treated with interferon therapy. *BES 2009, Endocrine Abstracts 19:P353 and ATA 2009).*
13. Development of audit tool for national study of pituitary apoplexy. Kumar S, Reddy N; Baldeweg S, Han T, Vanderpump M & Wass J. Validity of the new pituitary apoplexy guideline group scoring system (PAGGS) in the management of pituitary apoplexy: a large retrospective review of 46 patients with classical pituitary apoplexy. *BES 2010, Endocrine Abstracts 21:P284.*
14. Audit of introduction of TSH receptor antibody assay. Theodoraki K, Jones GL, Patel D, Bunn C, Thomas M, Parker J, Bouloux P-M & Vanderpump M. TSH Receptor Antibody assay: its use in a tertiary centre. *British Endocrine Societies 2010, Endocrine Abstracts 21:P389 and ITC, Paris, September 2010.*
15. Review of 125 individuals with adrenal incidentalomas: a single centre cohort. Theodoraki K, Jones GL, Patel D, Bunn C, Thomas M, Parker J, Bouloux P-M, Vanderpump M & Khoo B. *Society for Endocrinology BES March 2011, Endocrine Abstracts 25:P105.*
16. Clinical outcome of radioiodine treatment for Graves' disease at a tertiary care centre. Rathore A, Mathew R, Garg A & Vanderpump M. *Society for Endocrinology 2014. Endocrine Abstracts 34:P395.*
17. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. Drake WM, Stiles CE, Howlett TA, Toogood AA, Bevan JS & Steeds RP; UK Dopamine Agonist Valvulopathy Group (2014). *JCEM 99:90-96.*
18. The Royal Free Continuous Subcutaneous Insulin Infusion (CSII) Service: a comparison of patch pump vs traditional pump showing different population demographics, increased patch pump uptake in pregnancy and equal efficacy at reducing HbA1c. N Gostelow, L Williamson, J Holland, M Vanderpump & M Rosenthal. *BDA March 2014. P476*

19. A study on the management of differentiated thyroid cancer at a large UK Teaching Hospital. CL Chang, G Stewart, M Vanderpump, B Khoo, P-M Bouloux, D Afful & S Janmohamed. The Endocrine Society June 2014. P0570.

TEACHING

My clinical post had a teaching commitment for undergraduate students (Year 3) from the Royal Free Hospital and UCH Medical School. I performed regular interactive tutorial teaching to Medical Students and Junior Doctors.

National and international lectures on thyroid disease.

Ongoing seminars and lectures on Diabetes and its complications and Endocrine Disorders to Hospital Practitioners, General Practitioners and Practice Nurses.

Principal organiser of a Training Program for Endocrine Specialist Registrars in Northeast Thames rotation and served on the Specialist Training Committee for Endocrinology in North Thames from 1999-2004.

Responsibility for organising the thyroid module of the curriculum for Specialist Registrars in Endocrinology in Clinical Endocrinology Update (2007-2009).

Royal College of Physicians Tutor for the Royal Free Hospital from 2000-2003 and organiser of SHO training programme for the MRCP at the Royal Free Hospital which was highly commended by the RCP. As Unit Training Director in Medicine, the training opportunities provided by the generic night team in terms of leadership, team-building skills and managing the acutely sick were emphasised.

Internal Examiner for the finals in Pharmacology at UCH from 1999-2003 and External Examiner for B Med Sci Exam Board for Queen Mary College, University of London 2003-2005. Internal Examiner for the MD and PhD thesis for the University of London and an External Examiner for MD thesis for University of Dublin.

Founder and co-organiser of the Annual Pituitary Clinicopathological Conference 2000-19.

INVITED LECTURES

1. The Whickham survey follow-up - longitudinal studies of the epidemiology of thyroid disease. Thyroid Club, London, 1994.

2. Thyroid disease and diabetes in an English community - the Whickham study revisited. Endocrine Department, Mayo Clinic, USA, 1995.

3. The twenty-year follow-up of the Whickham survey. Belgium Thyroid Club, Brussels, 1997.

4. Screening for thyroid disease. UK NEQAS, Edinburgh, 1998.

5. Ischaemic heart disease and its relationship to autoimmune thyroid disease. Symposium of 4th European Congress of Endocrinology, Granada, 1998.

6. Subclinical thyroid disease. British Endocrine Societies, Bournemouth, 1999.
7. Epidemiology of nodular goitre. European Thyroid Association, Milan, 1999.
8. Population screening for autoimmune thyroid disease. Dutch Thyroid Club, Amsterdam, 1999.
9. Epidemiology of goitre and hypothyroidism. Merck European Thyroid Symposium, Budapest, 2000.
10. Screening for hypothyroidism. British Thyroid Association, London, 2000.
11. How to deal with an elevated TSH. The Glasgow Symposium on Endocrinology, Royal College of Physicians and Surgeons of Glasgow, Glasgow, 2001.
12. Subacute hypothyroidism in the elderly. The Endocrine Society, Denver, 2001.
13. Current knowledge on diagnosing and therapy of thyroid disorders in the UK. Satellite Meeting of European Thyroid Association, Aalborg, Denmark, 2001.
14. Management of differentiated thyroid cancer. 11th European Federation of Endocrine Societies Postgraduate Course in Endocrinology, Oxford, 2003.
15. EWTD compliance in Medicine and Surgery and development of night team at the Royal Free Hospital Trust. National Meeting of NHS Trust Medical Directors, Royal College of Physicians, London, 2003.
16. What to do with thyroid nodules and goitres. Advanced Medicine Conference, Royal College of Physicians, London, 2004.
17. Subclinical hypothyroidism. Joint Meeting of the British Thyroid Association and Irish Endocrine Society, Dublin, 2004.
18. Screening for hypothyroidism. Merck European Thyroid Symposium, Berlin, June 2004.
19. Meet the Expert - Subclinical hypothyroidism. The Endocrine Society, New Orleans, June 2004.
20. Practical management of common outpatient problems - "Tired all the Time". Oxford Advanced Endocrinology Seminar, Oxford, 2004.
21. "Weird thyroid function tests". General Internal Medicine for the Physician, Royal College of Physicians, London, 2004.
22. Evidence for diagnosis and management of subclinical thyroid disease. 16th IFCC-FESCC European Congress of Clinical Chemistry and Laboratory Medicine, Glasgow, 2005.
23. Thyroid dysfunction in the elderly. The Endocrine Society, San Diego, 2005.
<http://www.medscape.com/viewarticle/510284>
24. Screening for thyroid disease. Pathology Section of the Royal Society of Medicine, London, 2005.
25. Subclinical hypothyroidism. 13th International Thyroid Congress, Buenos Aires, 2005.

26. How I Manage - Thyroiditis. British Thyroid Association Annual Meeting, London, 2006.
27. Clinical Debate "This House believes that all patients with subclinical thyrotoxicosis should be treated: Against the Motion". British Endocrine Societies, Birmingham, 2007. <http://www.endocrine-abstracts.org/ea/0013/ea0013D2.htm>
28. UK Guidelines for Thyroid Function Tests. Association of Clinical Biochemists Focus 2007, Manchester, 2007.
29. The thyroid nodule - When and how to assess? Joint meeting of Royal College of Radiologists and Society for Endocrinology, London, 2007.
30. Elevated TSH - When do I start thyroxine? Endocrinology for the General Physician, Royal College of Physicians, London, 2007.
31. Diabetes and endocrine disorders in aging people - Management of goitre. Endocrinology and Diabetes Section of Royal Society of Medicine and Association of British Clinical Diabetologists, London, 2008.
32. Evidence-based medicine - Subclinical hypothyroidism. Endocrinology and Diabetes Section of Royal Society of Medicine, London, 2008.
33. Thyroid function and pregnancy - Epidemiology and iodine status. Merck European Thyroid Symposium, Riga, 2008.
34. New drugs and thyroid function. Meet the Expert. European Thyroid Association, Thelassonika, 2008.
35. Subclinical hypothyroidism. British Thyroid Association Annual Meeting, London, 2008.
36. Amiodarone and thyroid disorders. Association of Clinical Biochemists, London, 2009.
37. Adolescent thyroid disease. Northwest London Paediatric Endocrinologists. London, 2009.
38. Subclinical thyroid disease. Acute and General Internal Medicine for the Physician, Royal College of Physicians, London, 2009.
39. What's new in thyroid disease? Association of British Clinical Diabetologists. London, 2009.
40. Endocrine incidentalomas - Thyroid. British Endocrine Societies, Manchester, 2010.
41. Subclinical thyroid disease. Acute and General Internal Medicine for the Physician, Royal College of Physicians, Liverpool, 2010.
42. Thyroid emergencies. Endocrinology and Diabetes Section of RSM, London, 2010.
43. Medical management of thyroid eye disease. Royal Society of Medicine Squint symposium, London, 2011.
45. Weird thyroid function tests. Royal College of Physicians Update. Watford, 2011.
46. Amiodarone and thyroid disease. Clinical Update, Society for Endocrinology, Sheffield, 2011.

47. Meet the Expert - Amiodarone. British Endocrine Societies, Harrogate, 2012.
48. Thyroid eye disease - The Physicians perspective. Royal Society of Medicine, London, 2012.
49. How to interpret thyroid function tests. Royal College of Physicians of Edinburgh Acute Medicine Conference, Edinburgh, 2012.
50. Iodine deficiency - The problem and the solution. Association of British Clinical Diabetologists, Leeds, 2012.
51. Iodine status. American Thyroid Association, Quebec, 2012.
52. Goitre and thyroid nodules. Clinical Update, Society for Endocrinology, Stratford, 2012.
53. Thyroid function and iodine in fertility and miscarriage. Royal College of Obstetrics and Gynaecology, London, 2013.
54. Subclinical thyroid disease. Oxford Endocrinology Course, Oxford, 2013.
55. Thyroid disease update. Royal Society of Medicine GP update, London, 2013.
56. Diabetes mellitus. London Osteopathic Society, London, 2013.
57. Diabetes Update - Reviewing your approach to diabetes diagnosis. Pulse GP Conference, London, 2013.
58. Iodine nutrition in the UK. Society for Endocrinology/Irish Endocrine Society Clinical Cases Meeting, Belfast, 2013.
59. The management of patients with abnormal thyroid biochemistry and subclinical thyroid disease and those with continuing symptoms on thyroid hormone replacement. Royal Society of Medicine GP Conference, London, 2014.
60. Thyroid and the MAU. MRCP Teaching Symposium, Royal College of Physicians, London, 2014.
61. Thyroid and iodine nutritional status. Royal College of Physicians Advanced Medicine Conference, London, 2014.
62. HIV and diabetes. ICDC, London, 2014.
63. Thyroid disorders. London Osteopathic Society, London, 2014.
64. Diabetes Update - Reviewing your approach to diabetes diagnosis. Pulse GP Conference, Birmingham, 2014.
65. Vitamin D. Hospital of St John and St Elizabeth symposium, London, 2014
66. Thyroid and fertility. UCH Reproductive Medicine Group, London, 2014.
67. Endocrinology for General Physician - Subclinical thyroid disease: when would/should we intervene? Royal College of Physicians, London, 2014.
68. The Transgender Footballer. FA Medical Committee, Wembley, 2014.

69. Amiodarone-induced thyroid disease. Clinical Update, Society for Endocrinology, Manchester, 2014.
70. Common thyroid disorders. British Thyroid Association Clinical SpR Teaching Programme, London, 2014.
71. Management of benign thyroid disease - State-of-art. British Nuclear Medicine Society, Brighton, 2015.
72. Medicolegal aspects of diabetes including neuropathy. AvMA, London 2015.
73. UK iodine status. International Thyroid Congress, Orlando 2015.
74. Iodine deficiency. Society for Endocrinology, Edinburgh 2015.
75. Type 1 and type 2 diabetes. AvMA webinar, 2015.
76. Anti-thyroid drugs in pregnancy. Hammersmith Endocrine Symposium, 2015.
77. Iodine and the thyroid. Royal College of Obstetricians and Gynaecologists, 2016.
78. Thyroid hormone replacement - Controversies. Oxford Endocrinology Masterclass, 2016.
79. Thyroiditis. Society for Endocrinology, Brighton 2016.
80. Thyroid dysfunction in children. Excellence in Paediatrics, London 2016.
81. Medicolegal aspects of diabetes. Skeleton Medicolegal Series, 7BR, London 2017.
82. Thyroid and reproduction. CRGH, London 2017 and 2018.
83. Male menopause. Hospital of St John and St Elizabeth Annual Symposium. London 2017.
84. Drugs and thyroid disease. Clinical Update, Society for Endocrinology, Birmingham 2017.
85. Subclinical thyroid disease. Midlands Endocrine Club, Birmingham 2017.
86. Diabetes update. Independent Doctors Federation Conference, London 2017.
87. Hypothyroidism. RCP Update in Endocrinology, London 2017.
88. Immunotherapy related endocrinopathies. European Congress of Endocrinology, Barcelona 2018.
89. TSH suppression and use of radioiodine. New Developments and Controversies in the Management of Thyroid Cancer. Royal College of Physicians, London 2018.
90. Epidemiology, clinical picture, and diagnosis of hyperthyroidism. European Thyroid Association Clinical Update. Newcastle upon Tyne 2018.
91. Thyroid disease in children. Thyroid Federation International/European Thyroid Association, Newcastle upon Tyne 2018.
92. Adrenal fatigue. Independent Doctors Federation Conference, Milan 2018.
93. Thyroid storms. Royal College of Physicians, Edinburgh 2018.

94. Medical management of thyroid eye disease. Royal Society of Medicine Squint symposium, London, 2018.
95. Diabetic foot disease. AvMA, London 2019.
96. Calcium disorders. GP Refresher Course, Hammersmith Hospital. 2019.
97. Essential diabetes for lawyers. AvMA, London 2020.
98. Medio-legal issues in diabetes, 7BR Skeleton Series, London 2020-21.
99. Radioiodine v Surgery for Graves' thyrotoxicosis. Imperial Endocrine Symposium, London 2021.
100. Update on Autoimmune Thyroid Disorders, IDF Symposium, London 2022.
101. Amiodarone and thyroid dysfunction. British Thyroid Association, London 2023.
102. Update on thyroid disorders. Imperial Endocrine Symposium, London 2024.

RESEARCH

My MD thesis was an epidemiological twenty-year follow-up study of the Wickham survey which involved determining the outcome in terms of thyroid disorders, diabetes and cardiovascular disease in 2779 subjects. This has provided unique incidence data and risk factors for these disorders. My MD thesis submitted to the University of Birmingham in 1995 was titled "The Incidence of Thyroid Disorders and Diabetes Mellitus in the Community and the Relationship of Thyroid Failure with the Development of Ischaemic Heart Disease". Subsequently my main research interests have been epidemiology, clinical thyroid disease, audit, and the cost-effectiveness of managing thyroid disease.

BOOK

Vanderpump MPJ & Tunbridge WMG (2008). "Thyroid disease: The facts" 4th edition. Oxford University Press.

ORIGINAL PAPERS

1. Taylor R, Foster B, Kyne-Grzebalski D & Vanderpump MPJ (1994). Insulin regimens for the non-insulin dependent: Impact on diurnal metabolic state and quality of life. *Diabetic Med* 11:551-7.
2. Vanderpump MPJ, Tunbridge WMG, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge FT & Young ET (1995). The incidence of thyroid disorders in the community - a twenty-year follow-up of the Wickham survey. *Clin Endocrinol* 43:55-69. Abstract published in "1996 Year Book of Medicine", Mosby-Year Book, Inc. <http://www3.interscience.wiley.com/journal/119246864/abstract>
3. Vanderpump MPJ, Tunbridge WMG, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Rodgers H, Tunbridge FT & Young ET (1996). The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. *Thyroid* 6:155-60.

4. Vanderpump MPJ, Tunbridge WMG, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Rodgers H, Tunbridge FT & Young ET (1996). The incidence of diabetes mellitus in an English community - a twenty-year follow-up to the Whickham survey. *Diabetic Med* 13:741-7.
5. Vanderpump MPJ, Manning K, Neary RH & Clayton RN (1997). Does an increase in the sensitivity of serum thyrotrophin assays reduce diagnostic costs for thyroid disease in the community? *J Roy Soc Med* 90:547-550.
6. Vanderpump MPJ, French JM, Appleton D, Tunbridge WMG & Kendall-Taylor P (1998). The prevalence of hyperprolactinaemia and association with markers of autoimmune thyroid disease in survivors of the Whickham survey cohort. *Clin Endocrinol* 48:39-44.
7. Vanderpump MPJ, Alexander L, Scarpello JH & Clayton RN (1998). Audit of management of thyroid cancer in a large district general hospital. *Clin Endocrinol* 48:419-24.
8. Ramachandran S, French JM, Vanderpump MPJ, Croft P & Neary RH (2000). Using the Framingham model to predict heart disease in the United Kingdom: retrospective study. *BMJ* 320:676-7.
9. Ramachandran S, French JM, Vanderpump MPJ, Croft P & Neary RH (2000). Should treatment recommendations for lipid lowering drugs be based on absolute coronary risk or risk reduction? *BMJ* 320:677-9.
10. Clayton RN, Pfeifer M, Wass JAH, Vanderpump M, Kyridamou E, Simpson D & Farrell WE (2000). Human pituitary tumours have multiclonal origins. *Clin Cancer Res* 6:3973-82.
11. Beaumont NJ, Skinner VO, Tan T M-M, Ramesh BS, Byrne DJ, MacColl GS, Keen JN, Bouloux PM, Mikhailidis DP, Bruckdorfer KR, Vanderpump MP & Srai KS (2003). Ghrelin can bind to a species of high-density lipoprotein associated with paroxonase. *J Biol Chem* 278:8877-80.
12. Martin C, Vanderpump M & French J (2004). Description and validation of a Markov model of survival for individuals free of cardiovascular disease that uses Framingham risk factors. *BMC Medical Informatics Decision Making* 1472-6947/4/6.
13. Tan T M-M, Vanderpump M, Khoo B, Patterson M, Ghatei MA & Goldstone AP (2004). Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. *J Clin Endocrinol Metab* 89:4162-5.
14. Jones G, Vanderpump M, Easton M, Baker D, Ball C, Leenane M, O'Brien H, Turner N, Else M, Reid W & Johnson M (2004). A strategic approach to achieving compliance with the European Working Time Directive in a large teaching hospital with an acute admissions unit. *Clin Pract* 4:427-30.
15. Patel NN, Abraham P, Buscombe J & Vanderpump MPJ (2006). The cost-effectiveness of treatment modalities for thyrotoxicosis in a UK centre. *Thyroid* 16:593-98.
16. Madge S, Smith CJ, Lampe FC, Thomas M, Johnson MA, Youle M & Vanderpump MPJ (2007). No association between HIV disease and its treatment and thyroid function. *HIV Med* 8:22-7.

17. Razvi S, Shakoor A, Vanderpump M, Weaver J & Pearce S (2008). The influence of age on the relationship between subclinical hypothyroidism and ischaemic heart disease: A meta-analysis. *J Clin Endocrinol Metab* 93:2998-3007.
18. Costelloe S, Wassef N, Morris C, Schulz J, Vaghani T, Thomas M, Jacobs M, Dusheiko G & Vanderpump M (2010). Thyroid dysfunction in a UK hepatitis C population treated with interferon-alpha and ribavirin therapy. *Clin Endocrinol* 73:249-56.
19. Razvi S, Weaver J, Vanderpump M & Pearce S (2010). The incidence of ischaemic heart disease and mortality in people with subclinical hypothyroidism: a re-analysis of the Whickham cohort. *J Clin Endocrinol Metab* 95:1734-40.
20. Rodondi N, den Elzen WPJ; Bauer DC, Cappola AR, Razvi S, Walsh JP, Åsvold BO, Iervasi G, Imaizumi M, Collet T-H, Bremner A, Maisonneuve P, Sgarbi JA, Khaw K-T, Vanderpump PJ, Newman AB, Cornuz J, Franklyn JA, Westendorp RGJ, Vittinghoff E, Gussekloo J; for the Thyroid Studies Collaboration (2010). Subclinical hypothyroidism and the risk of coronary heart disease and mortality. *JAMA* 304:1365-74.
21. Theodoraki A, Jones G, Parker J, Woolman E, Martin N, Perera S, Khoo B, Thomas M, Bunn C, Bouloux PM & Vanderpump MPJ (2011). Performance of a third-generation TSH-receptor antibody assay in a UK clinic. *Clin Endocrinol* 75:127-33.
22. Reddy NL, Rajasekaran S, Han TS, Theodoraki A, Drake W, Vanderpump M, Baldeweg S & Wass JA (2011). An objective scoring tool in the management of patients with pituitary apoplexy. *Clin Endocrinol* 75:723.
23. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, Singh GM, Lin JK, Stevens GA, Riley LM, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Cholesterol) (2011). National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. *Lancet* 377:578-86.
24. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index) (2011). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. *Lancet* 377:557-67.
25. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, Farzadfar F, Stevens GA, Lim SS, Riley LM, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure) (2011). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. *Lancet* 377:568-77.
26. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose) (2011). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since

1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. *Lancet* 378:31-40.

27. Vanderpump MP, Lazarus JH, Smyth PP, Laurberg P, Holder RL, Boelaert K & Franklyn JA; British Thyroid Association UK Iodine Survey Group (2011). Iodine status of UK schoolgirls: a cross-sectional survey. *Lancet* 377:2007-12.

28. Theodoraki A, Khoo B, Hamda A, Schwappach A, Perera S, Vanderpump MP & Bouloux PM (2011). Outcomes in 125 individuals with adrenal incidentalomas from a single centre. a retrospective assessment of the 1mg overnight and low dose dexamethasone suppression tests. *Hormone Met Res* 43:962-9.

29. Stevens GA, Singh GM, Lu Y, Danaei G, Lin JK, Finucane MM, Bahalim AN, McIntire RK, Gutierrez HR, Cowan M, Paciorek CJ, Farzadfar F, Riley L, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index) (2012). National, regional, and global trends in adult overweight and obesity prevalences. *Population Health Metrics* 10:22.

30. Danaei G, Singh GM, Paciorek CJ, Lin JK, Cowan MJ, Finucane MM, Farzadfar F, Stevens GA, Riley LM, Lu Y, Rao M, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group. (2013). The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008. *Circulation* 127:1493-502.

31. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (2014). Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. *Lancet Diabet Endocrinol* 2:634-47.

32. Collet TH, Bauer DC, Cappola AR, Asvold BO, Weiler S, Vittinghoff E, Gussekloo J, Bremner A, den Elzen WP, Maciel RM, Vanderpump MP, Cornuz J, Dörr M, Wallaschofski H, Newman AB, Sgarbi JA, Razvi S, Völzke H, Walsh JP, Aujesky D, Rodondi N; Thyroid Studies Collaboration (2014). Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease: an individual participant data analysis. *J Clin Endocrinol Metab* 99:3353-62.

33. Åsvold BO, Vatten LJ, Bjørø T, Bauer DC, Bremner A, Cappola AR, Ceresini G, den Elzen WP, Ferrucci L, Franco OH, Franklyn JA, Gussekloo J, Iervasi G, Imaizumi M, Kearney PM, Khaw KT, Maciel RM, Newman AB, Peeters RP, Psaty BM, Razvi S, Sgarbi JA, Stott DJ, Trompet S, Vanderpump MP, Völzke H, Walsh JP, Westendorp RG, Rodondi N; Thyroid Studies Collaboration. (2015) Thyroid function within the normal range and risk of coronary heart disease: an individual participant data analysis of 14 cohorts. *Ann Intern Med* 175:1037-47.

34. Wopereis DM, Du Puy RS, van Heemst D, Walsh JP, Bremner A, Bakker SJL, Bauer DC, Cappola AR, Ceresini G, Degryse J, Dullaart RPF, Feller M, Ferrucci L, Floriani C, Franco OH, Iacoviello M, Iervasi G, Imaizumi M, Jukema JW, Khaw KT, Luben RN, Molinaro S, Nauck M, Patel KV, Peeters RP, Psaty BM, Razvi S, Schindhelm RK, van Schoor NM, Stott DJ, Vaes B, Vanderpump MPJ, Völzke H, Westendorp RGJ, Rodondi N, Cobbaert CM, Gussekloo J, den Elzen WPJ; Thyroid Studies Collaboration. (2018) The relation between thyroid function and anemia: pooled analysis of individual participant data. *J Clin Endocrinol Metab* 103:3658-67.

35. Zaman S, Patel B, Glynne P, Vanderpump M, Alsafi A, Khan S, Flora R, Palazzo F, Wernig F. (2020). A rare cause of severe Cushing's syndrome. *Endocrinol Diabetes Metab Case Rep.* 2020:20-0011.

36. Xu Y, Derakhshan A, Hysaj O, Wildisen L, Ittermann T, Pingitore A, Abolhassani N, Medici M, Kiemeny LALM, Rixsen NP, Dullaart RPF, Trompet S, Dörr M, Brown SJ, Schmidt B, Führer-Sakel D, Vanderpump MPJ, Muendlein A, Drexel H, Fink HA, Ikram MK, Kavousi M, Rhee CM, Bensenor IM, Azizi F, Hankey GJ, Iacoviello M, Imaizumi M, Ceresini G, Ferrucci L, Sgarbi JA, Bauer DC, Wareham N, Boelaert K, Bakker SJL, Jukema JW, Vaes B, Iervasi G, Yeap BB, Westendorp RGJ, Korevaar TIM, Völzke H, Razvi S, Gussekloo J, Walsh JP, Cappola AR, Rodondi N, Peeters RP, Chaker L; Thyroid Studies Collaboration. (2023). The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis. *Lancet Diabetes Endocrinol.* 11:743-54.

37. Razvi SS, Wild H, Ingoe L, Vernazza J, Vanderpump M, Pearce SHS, Ludgate M. (2024). Changes in thyroid function and autoimmunity in older individuals: longitudinal analysis of the Whickham cohort. *J Clin Endocrinol Metab* doi: 10.1210/clime/dgae875. Online ahead of print.

REVIEW ARTICLES

1. Vanderpump MPJ & Tunbridge WMG (1993). The effects of drugs on endocrine function. *Clin Endocrinol* 39:389-97.
2. Taylor R & Vanderpump MPJ (1994). New concepts in diabetes mellitus I: treatment, pregnancy and aetiology. *Postgrad Med J* 70:418-27.
3. Vanderpump MPJ & Taylor R (1994). New concepts in diabetes mellitus II: complications. *Postgrad Med J* 70:79-485.
4. Quinton R, Conway GS, Jacobs HS, Bouloux P-MG & Vanderpump MPJ (1998). Adult onset idiopathic hypogonadotrophic hypogonadism may be overdiagnosed. *BMJ* 317:600-1.
5. Tunbridge WMG & Vanderpump MPJ (2000). Population screening for autoimmune thyroid disease. *Endocrinol Metab Clinics N Am* 29:239-53.
6. Vanderpump MPJ & Tunbridge WMG (2002). Epidemiology and prevention of clinical and subclinical hypothyroidism. *Thyroid* 12:839-47.
7. Vanderpump MPJ (2003). Subclinical hypothyroidism - the case against treatment. *Trends Endocrinol Metab* 14:262-6.
8. Hameed S & Vanderpump MPJ (2003). Common problems managing thyroid disease in primary care. *Pulse* 63:26-31.
9. Vanderpump MPJ & Franklyn JA (2003). Restoring TSH to the reference range should be the goal of replacement. *BMJ* 326:1086-7.
10. Vanderpump MPJ (2004). Screening for thyroid dysfunction. In "Hot Thyroidology" Editorial No 2, July 2004, European Thyroid Association.

11. Patel N & Vanderpump MPJ (2005). Goitres and thyroid carcinoma. *Practitioner* 249:574-7.
12. Olateju TO & Vanderpump MPJ (2006). Thyroid hormone resistance. *Ann Clin Biochem* 43:431-40.
13. Vanderpump MPJ (2007). Invited editorial: Cardiovascular and cancer mortality after radioiodine in hyperthyroidism. *J Clin Endocrinol Metab* 92:2033-5.
14. Smellie WSA, Vanderpump MPJ, Fraser WD, Bowles R & Shaw N (2008). Best practice in primary care pathology: Review 11 Thyroid testing, hypercalcaemia and hypocalcaemia. *J Clin Path* 61:410-8.
15. Vanderpump MPJ (2008). Is thyroid autoimmunity associated with malignancy? *Nature Clin Pract Endocrinol Metab* 4:196-7.
16. Han TS, Williams GR & Vanderpump MPJ (2009). Benzofuran derivatives and the thyroid. *Clin Endocrinol* 70:2-13.
17. Vanderpump MPJ (2009). Epidemiology of thyroid dysfunction - Hypothyroidism and hyperthyroidism. *Thyroid International* 2-2009.
18. Vanderpump MPJ (2009). Use of glucocorticoids in amiodarone-induced thyrotoxicosis. *Nat Rev Endocrinol* 5:650-1
19. Vanderpump MPJ (2010). How should we manage patients with mildly increased serum thyrotrophin concentrations? *Clin Endocrinol* 72:436-440.
20. Vanderpump M, Higgins C & Wass JA (2011). UK guidelines for the management of pituitary apoplexy: A rare but potentially fatal medical emergency. *Emerg Med J* 28:550-1.
21. Vanderpump M (2011). Pharmacotherapy: Hypothyroidism - should levothyroxine be taken at bedtime? *Nat Rev Endocrinol* 7:195-6.
22. Vanderpump M (2011). The epidemiology of thyroid disease. *Br Med Bull* 99:39-51.
23. Vanderpump MP (2012). Should we treat mild subclinical/mild hyperthyroidism? No. *Eur J Intern Med* 22:330-3.
24. Vanderpump MPJ (2012). Key Questions - Thyroid disease. *Pulse* March, 2012
25. Vanderpump MPJ (2013). Hypothyroidism. *Pulse* July, 2013.
26. Vanderpump MPJ (2012). Iodine deficiency as a new challenge for industrialised countries: A UK perspective. *Intern J Epidemiol* 41:601-4.
27. Vanderpump MPJ (2012). Is lithium an effective adjunct therapy for radioiodine therapy for hyperthyroidism? *Clin Endocrinol* 77:513-4.
28. Garg A & Vanderpump MP (2013). Subclinical thyroid disease. *Br Med Bull* 107:101-6.
29. Vanderpump M (2014). Thyroid and iodine nutritional status: a UK perspective. *Clin Med* 14 Suppl 6:s7-s11.

30. Jefferys A, Vanderpump M & Yasmin E. (2015) Thyroid dysfunction and reproductive health. *The Obstetrician and Gynaecologist* 17:39-45.
31. Theodoraki A & Vanderpump MPJ. (2016) Thyrotoxicosis associated with the use of amiodarone: the utility of ultrasound in patient management. *Clin Endocrinol* 84:172–6.
32. Okosieme O, Gilbert J, Abraham P, Boelaert K, Dayan C, Gurnell M, Leese G, McCabe C, Perros P, Smith V, Williams G, Vanderpump M (2016). Management of primary hypothyroidism: Statement by the British Thyroid Association Executive Committee. *Clin Endocrinol* 84:799-808.
33. Parretti H, Okosieme O & Vanderpump M. (2016). Current recommendations in the management of hypothyroidism: developed from a statement by the British Thyroid Association Executive. *Br J Gen Pract* 66:538-40.
33. Vanderpump MP. (2017). Epidemiology of iodine deficiency. *Minerva Med* 108:116-123.
34. Prentice M, Hickey J, Vanderpump M, Taylor PN, Lazarus JH. Iodine and folate - essential for mothers to be. *Lancet Diabetes Endocrinol* 2020 8:9-10.

CHAPTERS

1. Vanderpump MPJ & Tunbridge WMG (1996). The epidemiology of thyroid diseases. In "Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text", 7/E. (Ed. LE Braverman and RD Utiger). JB Lippincott-Raven, Philadelphia, pp 474-82.
2. Vanderpump MPJ & Tunbridge WMG (1999). The epidemiology of autoimmune thyroid disease. In "The Autoimmune Endocrinopathies", chapter ed. R Volpe for "Volume of Contemporary Endocrinology" (Ed. PM Conn). Humana Press Inc, New Jersey, pp 141-62.
3. Vanderpump MPJ & Tunbridge WMG (2000). The epidemiology of thyroid diseases. In "Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text", 8/E. (Ed. LE Braverman and RD Utiger). JB Lippincott-Raven, Philadelphia, pp 467-73.
4. Vanderpump MPJ (2000). Epidemiology of goiter and hypothyroidism. In "The Thyroid and Environment". (Ed, F Peter, W Wiersinga, U Hostalek). Schattauer, Stuttgart, pp 3-13.
5. Vanderpump MPJ & Tunbridge WMG (2002). Epidemiology of thyroid disease and swelling. In "The Thyroid", chapter ed. WM Wiersinga for "Oxford Textbook of Endocrinology" 1st edition. (Ed. JAH Wass and SM Shalet). Oxford University Press, pp 339-49.
6. Vanderpump MPJ (2004). Epidemiology of thyroid diseases. In "Encyclopedia of Endocrinology and Endocrine Diseases" 1st edition. (Ed. L Martino and Assc. Ed. W Wiersinga). Elsevier Academic Press, Oxford, Vol 4 pp 401-8.
7. Vanderpump MPJ (2005). The Epidemiology of thyroid diseases. In "Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text", 9/E. (Ed. LE Braverman and RD Utiger). JB Lippincott-Raven, Philadelphia, pp 398-406.

8. Vanderpump MPJ (2005). What to do with thyroid nodules and goitres. In "Horizons in Medicine 16" (Ed. JA Franklyn). Royal College of Physicians, London, pp 55-62.
9. Vanderpump MPJ (2005). Screening for hypothyroidism: pros and cons. In "The Thyroid and Cardiovascular Risk". (Ed. K-M Derwahl, L Duntas and S Butz). Georg Thieme Verlag, Stuttgart, pp 15-23.
10. Vanderpump MPJ (2008). Hashimoto's thyroiditis and type 1 diabetes. In "Thyroid Underactivity", chapter ed. A Weetman for "A Case-Based Textbook of Clinical Endocrinology" (Ed. T Davis). Humana Press, Totawa, USA, pp 93-108.
11. Vanderpump MPJ (2009). Thyroid function and pregnancy. Epidemiology and iodine status. In "The Thyroid and Reproduction". (Ed, J Lazarus, V Pirags and S Butz). Georg Thieme Verlag, Stuttgart, pp 39-45.
12. Vanderpump MPJ (2011). Epidemiology of thyroid disease and swelling. In "The Thyroid", chapter ed. WM Wiersinga for "Oxford Textbook of Endocrinology" 2nd edition. (Ed. JAH Wass and PM Stewart). Oxford University Press, pp 358-70.
13. Vanderpump MPJ (2014). Thyroid. In "Oxford Handbook of Endocrinology and Diabetes", 3/E (Ed. J Wass and K Owen). Oxford Medical Publications, pp 1-105.
14. Theodoraki A & Vanderpump M (2014). Non-functioning pituitary tumour apoplexy. In "Pituitary Apoplexy" (Ed. M Turget, AK Mahapatra, M Powell, and N Muthukumar). Springer pp 25-33.
15. Theodoraki A & Vanderpump M (2014). Pituitary Apoplexy. In "Endocrine and Metabolic Medical Emergencies: A Clinician's Guide" 1st edition. (Ed. G Matfin). The Endocrine Society, pp 93-9.
16. Vanderpump MPJ (2015). Clinical Negligence: Endocrinology. In "Clinical Negligence", 5th edition (Ed. M Powers, N Harris, and A Barton). Tottel Publishing Ltd, pp 663-715.
17. Vanderpump MPJ. (2017). Thyroid disorders. In "Instant wisdom for GPs". (Ed. K Hopcroft). CRC Press.
18. Vanderpump M. (2018) Thyrotoxic periodic paralysis. In "Endocrine and Metabolic Medical Emergencies: A Clinician's Guide" 2nd edition. (Ed. G Matfin). Wiley-Blackwell, USA, pp 296-304.
19. Vanderpump MPJ. (2019) Epidemiology of thyroid disorders. In "The Thyroid and its Diseases". (Ed. M Luster, LH Duntas and L Wartofsky). Springer, Switzerland, pp 75-86.
20. Vanderpump MPJ. (2019) Epidemiology of thyroid disease. In "Encyclopaedia of Endocrinology and Endocrine Diseases" 2nd edition. (Ed. I Huhtaniemi and L Martini). Elsevier, Oxford. Vol. 4, pp. 486-495.
21. Vanderpump MPJ (2022). Epidemiology of thyroid disease and swelling. In "The Thyroid", chapter ed. WM Wiersinga for "Oxford Textbook of Endocrinology" 3rd edition. (Ed. JAH Wass, W Arlt and R Semple). Oxford University Press, pp 373-85.
22. Vanderpump MPJ (2022). Thyroid. In "Oxford Handbook of Endocrinology and Diabetes", (4th Ed. JAH Wass, K Owen, and K Turner). Oxford Medical Publications, pp 1-122.

23. Vanderpump MPJ (2023). Endocrinology. In "Clinical Negligence," 6th Edition. (Ed. M Powers and A Barton). Bloomsbury Professional Ltd, pp 753-91.
24. Vanderpump MPJ (2023). Thyroid disorders. In "Instant wisdom for GPs." 2nd Edition. (Ed. K Hopcroft). CRC Press, pp 217-23.